The use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to monitor the effectiveness of Lu-177-PSMA (Pluvicto) in treating prostate cancer led to a greater than 50 percent decrease in prostate-specific antigen (PSA) level for 60 percent of patients in a new study, noted Andrew Nguyen, MBBS, FRACP, AANMS, in a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
Single-photon emission computed tomography (SPECT) could play a significant role in monitoring and altering regimens for the use of Lu-177-PSMA (Pluvicto, Novartis) in treating metastatic castration-resistant prostate cancer (mCRPC).
In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Andrew Nguyen, MBBS, FRACP, AANMS, discussed findings from a new study that looked at the use of SPECT imaging and diagnostic computed tomography (CT) after weekly treatment with Lu-177-PSMA in 125 men with mCRPC. After the second dose in a six-week treatment plan, Dr. Nguyen and colleagues assessed imaging and prostate-specific antigen (PSA) levels to determine whether treatment should be continued or altered, according to the study.
Overall, the researchers said the use of early biomarkers to monitor treatment response led to 60 percent of patients having greater than 50 percent PSA reduction, a median PSA progression-free survival (PFS) of 6.1 months and a mean overall survival of 16.8 months.
For men who demonstrated a marked early reduction in PSA level and partial treatment response on SPECT imaging, they were allowed to cease treatment until PSA levels increased, necessitating re-treatment. Study findings revealed these patients had nearly double the median PSA-PFS (12.1 months) of patients who had a stable initial treatment response and proceeded to have the full six-week treatment course (6.1 months).
“These men could afford a treatment holiday with a mean of (6.1) months, potentially improving quality of life in men who may have treatment fatigue and side effects,” noted Dr. Nguyen, MBBS, FRACP, AANMS, a senior staff specialist in the Department of Theranostics and Nuclear Medicine at St. Vincent’s Hospital in Sydney, Australia.
(Editor’s note: For related content, see “Clarity Pharmaceuticals to Begin Phase 3 Trial for New PSMA PET Agent for Prostate Cancer,” “A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging” and “Deep Learning Network Shows Significant Potential for Prostate Cancer Detection on MRI.”)
For patients who had a rise in PSA level and progressive disease on SPECT imaging after initial treatment, Dr. Nguyen said they had limited PSA progression-free survival at 2.6 months. However, Dr. Nguyen pointed out that the opportunity to switch those who weren’t responding to initial treatment to alternative therapy led to “moderate” median survival of 11.2 months for this patient population.
“Identifying early disease progression using early response biomarkers may allow the opportunity for an alternative potentially effective treatment,” added Dr. Nguyen.
For more insights from Dr. Nguyen, watch the video below.
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.
SNMMI: Can Ultra-Low Dose PET Supplant the Need for CT Attenuation Correction?
June 11th 2024Ultra-low dosing with long axial field-of-view positron emission tomography (PET) scanners facilitates qualitative PET imaging at a more than 50 percent reduction of conventional radiation dosing with PET, according to new research presented at the SNMMI 2024 conference.
SNMMI: AI May Enhance Detection and Risk Assessment for Multiple Cancers on Whole-Body PET/CT Scans
June 10th 2024Deep transfer learning may elevate the capability of whole-body PET/CT scans to diagnose multiple cancers, ranging from breast cancer and lung cancer to melanoma and prostate cancer, according to new research presented at the SNMMI conference.
Siemens Healthineers Announces FDA Clearance for New PET/CT System at SNMMI Meeting
June 9th 2024Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.